Condition: Ankylosing Spondylitis (AS) · Sponsor: Tongji Hospital
The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in Chinese adults participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).
This description comes directly from the study's public registry record.
YU YIKAI, M.D · 15671678920 · yuyikai@163.com
Always discuss trial participation with your own doctor first.
| Department of RheumatologyTongji Hospital | Wuhan, Hubei, China | Recruiting |
| Tongji Hospital | Wuhan, Hubei, China | Recruiting |
| Tongji Hospital | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05303285